Valeant Pharmaceuticals International Inc (VRX.N) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International completes sale of filler and toxin assets to galderma


Thursday, 10 Jul 2014 09:30am EDT 

Valeant Pharmaceuticals International Inc:Completes sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 bln in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma.